<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02011841</url>
  </required_header>
  <id_info>
    <org_study_id>Rifaximin_SBP</org_study_id>
    <nct_id>NCT02011841</nct_id>
  </id_info>
  <brief_title>Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients</brief_title>
  <official_title>Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients: A Prospective, Multicenter, Randomized, Open-label, Controlled Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate whether long-term rifaximin administration reduces
      spontaneous bacterial peritonitis recurrence rate in cirrhotic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Rifaximin is an antibiotic with a broad-spectrum activity against gram-positive and
           gram-negative microorganisms, both aerobes and anaerobes within the gastrointestinal
           tract. The main advantage of rifaximin is that it is poorly absorbable, which minimizes
           the antimicrobial resistance and adverse events and renders the drug safe in all patient
           populations. In addition, rifaximin has a better activity against gram-positive
           organisms than norfloxacin.

        -  The appreciation of the potential role of enteric flora in the pathogenesis of several
           gastrointestinal diseases has broadened the clinical use of rifaximin, which is now used
           for hepatic encephalopathy, small intestine bacterial overgrowth, inflammatory bowel
           disease, and Clostridium difficile infection. Theoretically, by reducing the total
           number of the gut bacteria, rifaximin could also be used to achieve intestinal
           decontamination in patients with liver cirrhosis and ascites, thus preventing
           spontaneous bacterial peritonitis.

        -  A small retrospective study concluded that rifaximin suppresses intestinal bacterial
           overgrowth, bacterial translocation in cirrhotic patients with ascites with no history
           of previous spontaneous bacterial peritonitis episodes. Prospective clinical trials are
           warranted to evaluate the role of rifaximin for prevention of spontaneous bacterial
           peritonitis recurrence in cirrhotic patients.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    We failed to recruit patients
  </why_stopped>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The recurrence rate of spontaneous bacterial peritonitis</measure>
    <time_frame>every 4 weeks, up to 24 weeks</time_frame>
    <description>The proportion of patients who recurred spontaneous bacterial peritonitis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>All-cause mortality and cause-specific mortality (mortality due to spontaneous bacterial peritonitis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The recurrence of culture-negative spontaneous bacterial peritonitis</measure>
    <time_frame>every 4 weeks, up to 24 weeks</time_frame>
    <description>The proportion of patients who recurred culture-negative spontaneous bacterial peritonitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Causative bacteria of recurrent spontaneous bacterial peritonitis</measure>
    <time_frame>every 4 weeks, up to 24 weeks</time_frame>
    <description>Causative bacteria of recurrent spontaneous bacterial peritonitis and susceptibility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of gut microbiota</measure>
    <time_frame>at baseline, week 12</time_frame>
    <description>Gut microbiota will be analyzed at baseline and week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections other than spontaneous bacterial peritonitis</measure>
    <time_frame>every 4 weeks, up to 24 weeks</time_frame>
    <description>Infections other than spontaneous bacterial peritonitis (i.e. urinary tract infection, respiratory tract infection, etc.)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Spontaneous Bacterial Peritonitis</condition>
  <arm_group>
    <arm_group_label>Rifaximin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifaximin 1200 mg/day orally for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ciprofloxacin 500 mg/day orally for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>rifaximin 1200 mg/day orally for 6 months</description>
    <arm_group_label>Rifaximin group</arm_group_label>
    <other_name>Normix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>ciprofloxacin 500 mg/day orally for 6 months</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with cirrhosis based on clinical, biochemical, ultrasonographic
             and/or histological criteria

          -  Patients who had recovered from an episode of spontaneous bacterial peritonitis

          -  Age &gt; 18 and &lt;80 years

        Exclusion Criteria:

          1. Decompensated cirrhotic patients with

               -  serum bilirubin &gt; 3.2 mg/dL

               -  prothrombin time &lt; 25%

               -  serum creatinine &gt; 3 mg/dL

          2. Active gastrointestinal bleeding

          3. Hepatic encephalopathy &gt; grade 2

          4. Patients who have clinical, biochemical or radiological data suggesting hepatocellular
             carcinoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong-Hoon Lee, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2013</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jeong-Hoon Lee</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>liver cirrhosis</keyword>
  <keyword>ascites</keyword>
  <keyword>spontaneous bacterial peritonitis</keyword>
  <keyword>recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

